Industry
Over 25% of ISCT's membership and Annual Meeting attendees are comprised of industry partners with the remainder of our membership stemming from research principle investigators, laboratory, regulatory and clinical disciplines within cell therapy.
ISCT has the development experience and knowledge through its membership base to develop concensus on scientific standards and policy, and coordinate solutions to commercialization roadblocks to significantly advance the field of regenerative medicine.
ISCT’s New Vision for Industry Partnership
ISCT has elected to pursue a greater strategic alignment with its industry members, and in March 2010 an industry task force (ITF) was convened to address current and future roles for industry within the society. The ITF was composed of professionals participating in commercialization efforts with emphasis on international participation and was designed to include the spectrum of stakeholders in both the private and public setting.
The Task Force unveiled its recommendations at the May 2010 annual meeting. View the presentation. The full paper reviewing the commercialization issues and how ISCT proposes to address them in partnership with industry will be published in Cytotherapy November 2010. Download the abstract.
The NEW ISCT Industry Community
ISCT has launched a sponsorship based participation network for industry to:
- Replace traditional ISCT corporate membership with a more valuable peer to peer industry network.
- Offers access to Key Opinion Leaders (KOLs) in cell therapy translation including regulatory, scientific, process development and clinical experts.
- Drive priorities on the development of resources and initiatives to remove key obstacles to commercialization.
Click here for further information on the Industry Community.
